FOXO TECHNOLOGIES INC. ANNOUNCES CLOSING OF VECTOR BIOSOURCE INC.

Core Viewpoint - FOXO Technologies Inc. has successfully completed the acquisition of Vector Biosource Inc., a provider of information, data, and biospecimen sourcing for the biotechnology and pharmaceutical research sectors, with expectations for significant growth post-acquisition [1][2]. Acquisition Details - The total purchase price for Vector includes: - $500,000 in cash - 60,000 shares of Series E Preferred Stock valued at $1.5 million - Warrants to purchase $2 million of common stock at a 10% premium - Up to an additional 80,000 shares of Series E Preferred Stock, contingent on achieving specific revenue and cash collection milestones within 12 to 24 months - FOXO will also fund up to $1.2 million for Vector's growth initiatives [2]. Financial Performance - Vector generated net revenues of approximately $225,000 in Q2 2025, translating to an annual run rate of about $0.9 million, indicating potential for significant growth following the acquisition [1][2]. Company Background - FOXO operates three main subsidiaries: - Rennova Community Health, which runs a critical access hospital in East Tennessee - Myrtle Recovery Centers, a behavioral health facility providing various treatment services - FOXO Labs, focused on biotechnology and health improvement through innovative technology [4][5]. Management Statements - FOXO's CEO expressed enthusiasm about the acquisition and the potential for growth through collaboration with Vector's management [2]. - Vector's CEO highlighted the partnership with FOXO as a means to achieve aggressive growth plans [2].